[CAS NO. 82956-11-4] Nafamostat mesilate (FUT-175)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [82956-11-4]
Store
Catalog
SLK-S1386
Brand
Selleck
CAS
82956-11-4
DESCRIPTION [82956-11-4]
Overview
| MDL | MFCD00941430 |
|---|---|
| Molecular Weight | 539.58 |
| Molecular Formula | C19H17N5O2.2CH4O3S |
| SMILES | S(C)(=O)(=O)O.C(=N)(N)C1=CC2=C(C=C(OC(=O)C3=CC=C(NC(=N)N)C=C3)C=C2)C=C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8533 mL | 9.2665 mL | 18.5329 mL |
| 5 mM | 0.3707 mL | 1.8533 mL | 3.7066 mL |
| 10 mM | 0.1853 mL | 0.9266 mL | 1.8533 mL |
| 50 mM | 0.0371 mL | 0.1853 mL | 0.3707 mL |
Description
Nafamostat mesilate (Futhan, FUT-175) is a synthetic inhibitor, used as an anticoagulant during hemodialysis. Nafamostat mesylate blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. Nafamostat Mesilate attenuates inflammation and .
Targets
| serine protease [1] |
In vitro
Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa. Nafamostat mesilate inhibits several proteases which may be importantly involved in the pathophysiology of disseminated intravascular coagulation (DIC).Nafamostat mesilate inhibits extrinsic pathway activity (TF-F.VIIa mediated-F.Xa generation) in a concentration dependent manner with IC50 of 0.1 μM. Nafamostat mesilate produces concentration-dependent inhibition of the initial-phase transient component of biphasic ASIC3 currents with an IC50 value of approximately 2.5 mM.
References
[1] Sundaram S, et al. Thromb Haemost, 1996, 75(1), 76-82.
[2] Uchiba M, et al. Thromb Res, 1994, 74(2), 155-161.
[3] Ugawa S, et al. Biochem Biophys Res Commun, 2007, 363(1), 203-208.
[4] Ui H, et al. Eur J Pharmacol, 2006, 530(1-2), 172-178.
[5] Uwagawa T, et al. Anticancer Res, 2009, 29(8), 3173-3178.
[6] Markus Hoffmann, et al. Antimicrob Agents Chemother . 2020 May 21;64(6):e00754-20.
[7] Dong L, et al. Nat Commun. 2022 Aug 16;13(1):4804.
[2] Uchiba M, et al. Thromb Res, 1994, 74(2), 155-161.
[3] Ugawa S, et al. Biochem Biophys Res Commun, 2007, 363(1), 203-208.
[4] Ui H, et al. Eur J Pharmacol, 2006, 530(1-2), 172-178.
[5] Uwagawa T, et al. Anticancer Res, 2009, 29(8), 3173-3178.
[6] Markus Hoffmann, et al. Antimicrob Agents Chemother . 2020 May 21;64(6):e00754-20.
[7] Dong L, et al. Nat Commun. 2022 Aug 16;13(1):4804.
Synonyms
Benzoic acid, 4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester, methanesulfonate (1:2)
Benzoic acid, 4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dimethanesulfonate
FUT 175
Nafamostat mesylate
Nafamostat mesilate
6-Amidino-2-naphthyl p-guanidinobenzoate
Futhan
Nafamostat dimethanesulfonate
Nafamastat mesylate
Coahibitor
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.